View all newsletters
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
The Russian invasion of Ukraine has knock-on effects on the Covid-19 pandemic as supplies of Sputnik V vaccine to Asian, African, and South American countries are…
By
A quarter of haematological cancer patients do not mount an effective immune response after Covid-19 vaccination.
By
Post-Covid changes including social distancing measures and seasonal shifts have challenged RSV vaccine development projects.
By
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
A large study evaluating AstraZeneca’s Covid-19 monoclonal antibody will soon have data on its use in hospitalised patients.
By
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
By
The firms may struggle to convince regulators that their HIF PHIs don't share roxadustat’s safety concerns in CKD.
By
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
ByThank you for subscribing to Clinical Trials Arena